The Gateway To Europe: How Cryoport Systems' Stevenage Supply Chain Hub Supports ATMP Development

For UK-based Advanced Therapy Medicinal Product (ATMP) developers, seamless access to European clinical trial sites and commercial markets is essential for sustained growth and global competitiveness. However, navigating the intricate landscape of regulatory requirements, customs protocols, and supply chain logistics presents significant challenges. These complexities can lead to costly delays, jeopardize compliance, and compromise the integrity of highly sensitive biologics — ultimately impacting patient access to life-changing therapies.

Recognizing these challenges, Cryoport Systems has strategically established a state-of-the-art Good Manufacturing Practice (GMP)-compliant Global Supply Chain Hub in Stevenage, UK. Situated within one of Europe’s premier bioscience clusters, this facility serves as a central logistics hub, offering specialized support in regulatory compliance, risk mitigation, and supply chain optimization. By providing UK ATMP developers with streamlined access to European markets, Cryoport Systems empowers them to scale efficiently, accelerate commercialization, and deliver cutting-edge therapies to patients across the region with greater speed and reliability.